Cargando…
Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates
PURPOSE: To evaluate the long-term safety of vascular endothelial growth factor (VEGF) suppression with sustained aflibercept expression after a single intravitreal injection (IVI) of ADVM-022, an anti-VEGF gene therapy, in non-human primates (NHPs). METHODS: Non-human primates received bilateral IV...
Autores principales: | Kiss, Szilárd, Oresic Bender, Kristina, Grishanin, Ruslan N., Hanna, Kelly M., Nieves, Julio D., Sharma, Pallavi, Nguyen, Aivan T., Rosario, Romeo J., Greengard, Judith S., Gelfman, Claire M., Gasmi, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846953/ https://www.ncbi.nlm.nih.gov/pubmed/33532145 http://dx.doi.org/10.1167/tvst.10.1.34 |
Ejemplares similares
-
Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020) -
Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema
por: Gelfman, Claire M., et al.
Publicado: (2021) -
Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration
por: Grishanin, Ruslan, et al.
Publicado: (2019) -
The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes
por: Karakurt, Yucel, et al.
Publicado: (2018) -
Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
por: Gyenes, Andrea, et al.
Publicado: (2023)